Coverage
-
November 12, 2019
Canadian drugmaker Intellipharmaceutics International Inc. has agreed to pay investors $1.6 million to settle a proposed class action alleging the company overstated opioid painkiller Rexista's ability to deter abuse before the U.S. Food and Drug Administration rejected its approval.
1 other articles on this case.
View all »